Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles for the co-delivery of DOX/CPT-PEG for targeting HepG2 cells
Autor/a
Sánchez García, David
Borrós i Gómez, Salvador
Fornaguera Puigvert, Cristina
Martínez Edo, Gabriel
Otros/as autores/as
Universitat Ramon Llull. IQS
Fecha de publicación
2020-11Resumen
A pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX.
Tipo de documento
Artículo
Versión publicada
Lengua
English
Materias (CDU)
539 - Constitución física de la materia
616 - Patología. Medicina clínica. Oncología
Palabras clave
Nanopartícules
Doxorubicina
Medicaments
Càncer
Mesoporous silica nanoparticles
Dual release
Doxorubicin
Camptothecin
Anticancer drugs
Combination therapy
Targeting systems
Páginas
17 p.
Publicado por
MDPI
Publicado en
Pharmaceutics. Vol.12, n.11 (2020), 1048
Número del acuerdo de la subvención
info:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017-SGR-01559
Este ítem aparece en la(s) siguiente(s) colección(ones)
Derechos
© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/